MedTrace Logo

Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain

NCT05311774 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-12-03

No results posted yet for this study

Summary

Cancer pain is one of the most common and problematic symptoms. Opioids are typically the most common drugs used in the treatment of cancer pain,they are limited due to their side effects.

Tramadol is a centrally acting non-opiate analgesic with low affinity for μ-opioid receptors, and is effective in the treatment of moderate to severe pain.

Neuropathic pain is typically not amenable to standard opiate therapy, and the addition of tricyclic antidepressants or/and antiepileptic drugs can offer a very effective treatment strategy in such patients.

Duloxetine is a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) that has been used traditionally for its antidepressant qualities and has also analgesic benefit in the treatment of neuropathic pain. Duloxetine exerts its analgesic action through central and peripheral pain modulation .

Conditions

  • Cancer Pain

Interventions

DRUG

Placebo

tablet

DRUG

Duloxetine 30 mg

tablet

DRUG

Tramadol

tablet

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • khaled M Fares, MD · Assiut University

  • Ahmad M Abd EL Rahman, MD · Assiut University

  • Diab F Hetta, MD · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2025-10-01
Completion
2025-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05311774 on ClinicalTrials.gov